Evaluating FET PETCT Imaging to Detect Pituitary Adenomas in Adults with Cushing Disease

What this Trial Is About

Researchers are evaluating how well FET PETCT imaging detects ACTH-secreting pituitary adenomas in adults with Cushing disease. This early phase 1 diagnostic study aims to compare the imaging results against surgical findings and tissue analysis to determine accuracy, sensitivity, and specificity in locating these tumors. Participants will receive an intravenous dose of radiolabeled Fluoro-O-2 fluoroethyl-L-tyrosine FET about 20 minutes before undergoing PETCT imaging focused on the pituitary gland. This scan will be performed before planned pituitary surgery, which serves as the reference for confirming tumor presence. During the study, participants will undergo FET PETCT imaging and have recent or pending pituitary MRI scans for comparison. Researchers will analyze imaging results against histopathology from surgery to assess detection performance. The study will continue until primary outcomes are evaluated, with participant involvement lasting through the imaging and surgical procedures.

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease